Filing Flows › Evolent Health (EVH) › Guidance & outlook
Evolent Health (EVH) guidance and outlook
Evolent Health (EVH) raised its guidance on Nov 5, 2026: Revenue $2.6B–$2.7B for FY2026; EBITDA $130M–$135M for FY2026. Evolent Health's 10-Q filed Nov 5, 2026 makes 9 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $2.6B–$2.7B | reaffirmed |
| EBITDA | FY2026 | $130M–$135M | raised |
From the earnings release filed Nov 5, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 5, 2026
- We are unable to predict how these broader dynamics will impact our business and results of operations in the future, but they could continue to impact our financial condition and results of operations and such future impacts could be material.
- Generally, we will apply the series guidance to the performance obligation as we have determined that each time increment is distinct.
- As such, we are the principal and we will recognize revenue on a gross basis.
- In accordance with the series guidance, we allocate variable consideration to the period to which the fees relate.
- Our cost of revenue increased as a percentage of our total revenue due to the maturation profile of two new Performance Suite contracts that went live during the first half of 2026 We anticipate continued growth in the cost of treatment for cancer and cardiovascular patients over time, which we expect to be offset by contractual protections within our Performance Suite and the impact of our clinical interventions.
- We anticipate continued growth in the cost of treatment for cancer and cardiovascular patients over time, which we expect to be offset in part by contractual protections within our Performance Suite and the impact of our clinical interventions.
- We expect, from time to time, to seek to prepay, redeem, refinance, retire or purchase our outstanding debt through cash purchases and/or exchanges for equity or debt, in open-market purchases, privately negotiated transactions or otherwise.
- We believe that the amount of cash and cash equivalents on hand and cash flows from operations, plus borrowings under our credit facilities and if necessary, additional funding through other forms of financing, will be adequate for us to execute our business strategy and meet anticipated requirements for lease obligations, capital expenditures working capital and debt service for the next twelve
- The Company does not anticipate paying a cash dividend on our Class A common stock in the foreseeable future.
Evolent Health's latest quarter
Evolent Health, Q3 2026: revenue $725M (+51% year over year), operating margin -0.9%, net loss $23.6M, operating cash flow $26.4M. The chart follows the revenue to costs, profit and cash.
Questions
Did Evolent Health raise or lower its guidance?
Evolent Health (EVH) raised its guidance on Nov 5, 2026: Revenue $2.6B–$2.7B for FY2026; EBITDA $130M–$135M for FY2026.
What does Evolent Health expect?
We are unable to predict how these broader dynamics will impact our business and results of operations in the future, but they could continue to impact our financial condition and results of operations and such future impacts could be material. Generally, we will apply the series guidance to the performance obligation as we have determined that each time increment is distinct. As such, we are the principal and we will recognize revenue on a gross basis.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.